Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback